Hong-Liang Chen1, Ang Ding1, Fu-Wen Wang1. 1. Department of Breast Surgery, Obstetrics and Gynecology Hospital of Fudan University, Shanghai 200011, China.
Abstract
OBJECTIVE: To make a prognostic effect analysis of molecular subtype on young breast cancer patients. METHODS: Totally 187 cases of young breast cancer patients less than 40 years old treated in Obstetrics and Gynecology Hospital of Fudan University between June 2005 and June 2011 were included in our study. We described their clinical-pathological characteristics, disease-free survival (DFS) rate, and overall survival (OS) rate after a median follow-up period of 61 months. The factors associated with prognosis were also evaluated by univariate and multivariate analyses. RESULTS: All patients were premenopausal, with an average age of 35.36±3.88 years old. The mean tumor size was 2.43±1.53 cm. Eighty-one cases had lymph node metastasis (43.3%), 126 cases had lymphovascular invasion (67.4%), and 125 cases had histological grade III (66.8%) disease. Twenty-seven cases (14.4%) were Luminal A subtype, 99 cases (52.9%) were Luminal B subtype, 29 cases (15.5%) were human epidermal growth factor receptor 2 (HER-2) overexpression subtype, while 32 cases (17.1%) were triple negative breast cancer (TNBC) subtype according to 2013 St Gallen expert consensus. One hundred and thirty-five cases underwent mastectomy whereas 52 cases had breast-conserving surgery. One hundred and seventy-eight cases underwent adjuvant or neoadjuvant chemotherapy. Recurrence or metastasis occurred in 29 cases, 13 of which died. The 5-year DFS and OS rates were 84% and 92%. Multivariate analysis showed that nodal status (P=0.041) and molecular subtype (P=0.037) were both independent prognostic factors of DFS, while nodal status (P=0.037) and TNBC subtype (P=0.048) were both independent prognostic factors of OS. CONCLUSIONS: Molecular subtype is an independent prognostic factor of young breast cancer patients. TNBC has a high risk of relapse and death.
OBJECTIVE: To make a prognostic effect analysis of molecular subtype on young breast cancerpatients. METHODS: Totally 187 cases of young breast cancerpatients less than 40 years old treated in Obstetrics and Gynecology Hospital of Fudan University between June 2005 and June 2011 were included in our study. We described their clinical-pathological characteristics, disease-free survival (DFS) rate, and overall survival (OS) rate after a median follow-up period of 61 months. The factors associated with prognosis were also evaluated by univariate and multivariate analyses. RESULTS: All patients were premenopausal, with an average age of 35.36±3.88 years old. The mean tumor size was 2.43±1.53 cm. Eighty-one cases had lymph node metastasis (43.3%), 126 cases had lymphovascular invasion (67.4%), and 125 cases had histological grade III (66.8%) disease. Twenty-seven cases (14.4%) were Luminal A subtype, 99 cases (52.9%) were Luminal B subtype, 29 cases (15.5%) were humanepidermal growth factor receptor 2 (HER-2) overexpression subtype, while 32 cases (17.1%) were triple negative breast cancer (TNBC) subtype according to 2013 St Gallen expert consensus. One hundred and thirty-five cases underwent mastectomy whereas 52 cases had breast-conserving surgery. One hundred and seventy-eight cases underwent adjuvant or neoadjuvant chemotherapy. Recurrence or metastasis occurred in 29 cases, 13 of which died. The 5-year DFS and OS rates were 84% and 92%. Multivariate analysis showed that nodal status (P=0.041) and molecular subtype (P=0.037) were both independent prognostic factors of DFS, while nodal status (P=0.037) and TNBC subtype (P=0.048) were both independent prognostic factors of OS. CONCLUSIONS: Molecular subtype is an independent prognostic factor of young breast cancerpatients. TNBC has a high risk of relapse and death.
Entities:
Keywords:
Molecular subtype; prognosis; young breast cancer
Authors: Leonel F Hernandez-Aya; Mariana Chavez-Macgregor; Xiudong Lei; Funda Meric-Bernstam; Thomas A Buchholz; Limin Hsu; Aysegul A Sahin; Kim-Anh Do; Vicente Valero; Gabriel N Hortobagyi; Ana Maria Gonzalez-Angulo Journal: J Clin Oncol Date: 2011-05-23 Impact factor: 44.544
Authors: C M Perou; T Sørlie; M B Eisen; M van de Rijn; S S Jeffrey; C A Rees; J R Pollack; D T Ross; H Johnsen; L A Akslen; O Fluge; A Pergamenschikov; C Williams; S X Zhu; P E Lønning; A L Børresen-Dale; P O Brown; D Botstein Journal: Nature Date: 2000-08-17 Impact factor: 49.962
Authors: S Aebi; S Gelber; M Castiglione-Gertsch; R D Gelber; J Collins; B Thürlimann; C M Rudenstam; J Lindtner; D Crivellari; H Cortes-Funes; E Simoncini; I D Werner; A S Coates; A Goldhirsch Journal: Lancet Date: 2000-05-27 Impact factor: 79.321
Authors: E Shelley Hwang; Daphne Y Lichtensztajn; Scarlett Lin Gomez; Barbara Fowble; Christina A Clarke Journal: Cancer Date: 2013-01-28 Impact factor: 6.860
Authors: Carey K Anders; David S Hsu; Gloria Broadwater; Chaitanya R Acharya; John A Foekens; Yi Zhang; Yixin Wang; P Kelly Marcom; Jeffrey R Marks; Phillip G Febbo; Joseph R Nevins; Anil Potti; Kimberly L Blackwell Journal: J Clin Oncol Date: 2008-07-10 Impact factor: 44.544
Authors: Jeffrey Q Cao; Pauline T Truong; Ivo A Olivotto; Robert Olson; Genevieve Coulombe; Mira Keyes; Lorna Weir; Karen Gelmon; Vanessa Bernstein; Ryan Woods; Caroline Speers; Scott Tyldesley Journal: Int J Radiat Oncol Biol Phys Date: 2014-09-03 Impact factor: 7.038
Authors: R Peto; C Davies; J Godwin; R Gray; H C Pan; M Clarke; D Cutter; S Darby; P McGale; C Taylor; Y C Wang; J Bergh; A Di Leo; K Albain; S Swain; M Piccart; K Pritchard Journal: Lancet Date: 2011-12-05 Impact factor: 79.321
Authors: Massimiliano D'Aiuto; Andrea Chirico; Michele Antonio De Riggi; Giuseppe Frasci; Michelino De Laurentiis; Maurizio Di Bonito; Patrizia Vici; Laura Pizzuti; Domenico Sergi; Marcello Maugeri-Saccà; Maddalena Barba; Antonio Giordano Journal: Cancer Biol Ther Date: 2016-03-02 Impact factor: 4.742